Systemic Clinical Manifestations and Treatment of Granulomatosis with Polyangiitis: A Case Report

  • Wei Chern Ang Clinical Research Centre, Ministry of Health Malaysia, Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia. Department of Pharmacy, Hospital Tuanku Fauziah, Ministry of Health Malaysia, Kangar, Perlis, Malaysia. Department of Pharmacy, Hospital Sultanah Bahiyah, Ministry of Health Malaysia, Alor Setar, Kedah, Malaysia
  • Malathi Sriraman Department of Pharmacy, Hospital Sultanah Bahiyah, Ministry of Health Malaysia, Alor Setar, Kedah, Malaysia. Pharmacy Unit, Kuala Lumpur Health Clinic, Ministry of Health Malaysia, Kuala Lumpur, Malaysia
Keywords: Granulomatosis with polyangiitis, Immunosuppression, Anti-infective agents, Granuloma

Abstract

Granulomatosis with polyangiitis (GPA) is a granulomatous disorder linked with systemic necrotizing vasculitis with varied initial manifestations. We describe a case of a 49-year-old Malay female patient who gradually developed more symptoms of GPA over the past 14 years. This case emphasizes early detection and optimal treatment to minimize any further complications of GPA.

Author Biography

Wei Chern Ang, Clinical Research Centre, Ministry of Health Malaysia, Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia. Department of Pharmacy, Hospital Tuanku Fauziah, Ministry of Health Malaysia, Kangar, Perlis, Malaysia. Department of Pharmacy, Hospital Sultanah Bahiyah, Ministry of Health Malaysia, Alor Setar, Kedah, Malaysia
Research Pharmacist

References

Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis. 2011;70(4):704.

Loke YK, Tan MH. An unusual case of Wegener's granulomatosis. Med J Malaysia. 1998;53:107-9.

Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, et al. Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis. Semin Arthritis Rheum. 2002;47:320-5.

Chan AY, Li EK, Choi PC, Liu DT, Lam PT, Lam DS. Unusual eye signs in Wegener's granulomatosis. Hong Kong Med J 2007;13(3):241-2.

Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Semin Arthritis Rheum. 1990;33:1101-7.

de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Annals of internal medicine. 2009;150(10):670-80.

Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44.

De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52(8):2461-9.

Seror R, Pagnoux C, Ruivard M, et al. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis. 2010;69:2125-30.

Geetha D, Kallenberg C, Stone JH, et al. Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol. 2015; 28: 17–27.

Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221–232.

Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211–22

Published
2018-12-12
How to Cite
1.
Ang WC, Sriraman M. Systemic Clinical Manifestations and Treatment of Granulomatosis with Polyangiitis: A Case Report. J Pharm Care. 6(1-2):34-36.
Section
Case Report(s)